Mr. Morgan currently serves as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in Alpharetta, Georgia. Mr. Morgan also currently serves on the board of directors of Alimera Sciences, Inc., where he serves as a director and member of the company's Compensation Committee, and Health Outlook Corporation, a privately-held developer of predictive healthcare technology and service based in New York, New York, where he serves as a director and chair of the company's audit committee. Previously, Mr. Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and Pharmaceutical sectors, from February 2018 to June 2020. Prior to that, Mr. Morgan served as Senior Analyst at Iguana Healthcare Partners LLC, a healthcare-dedicated investment firm based in New York, New York, where he covered Medical Devices and Specialty Pharmaceuticals, from 2015 to January 2018. Mr. Morgan also served as an Analyst at Pura Vida Investments, LLC, a healthcare-focused investment firm, where he covered global Medical Devices, from 2014 to 2015. Earlier in his career, Mr. Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firm's Medical Supplies and Devices team, from January 2014 to June 2014. Mr. Morgan received his B.S. in Chemistry from the University of Minnesota and his MBA from the Carlson School of Management at the University of Minnesota.
What is Adam Morgan's net worth?
The estimated net worth of Adam Morgan is at least $11.47 million as of August 8th, 2025. Mr. Morgan owns 8,753,290 shares of Heron Therapeutics stock worth more than $11,466,810 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Morgan may own. Learn More about Adam Morgan's net worth.
How do I contact Adam Morgan?
Has Adam Morgan been buying or selling shares of Heron Therapeutics?
Adam Morgan has not been actively trading shares of Heron Therapeutics during the last quarter. Most recently, on Friday, August 8th, Adam Morgan bought 1,766,546 shares of Heron Therapeutics stock. The stock was acquired at an average cost of $1.50 per share, with a total value of $2,649,819.00. Following the completion of the transaction, the director now directly owns 8,753,290 shares of the company's stock, valued at $13,129,935. Learn More on Adam Morgan's trading history.
Who are Heron Therapeutics' active insiders?
Are insiders buying or selling shares of Heron Therapeutics?
In the last year, Heron Therapeutics insiders bought shares 2 times. They purchased a total of 4,153,771 shares worth more than $6,230,656.50. The most recent insider tranaction occured on August, 8th when Director Adam Morgan bought 1,766,546 shares worth more than $2,649,819.00. Insiders at Heron Therapeutics own 5.9% of the company.
Learn More about insider trades at Heron Therapeutics. Information on this page was last updated on 8/8/2025.
